Immupharma PLC Repayment of Convertible Security (6518Z)
September 22 2020 - 2:00AM
UK Regulatory
TIDMIMM
RNS Number : 6518Z
Immupharma PLC
22 September 2020
22 September 2020
ImmuPharma plc
("ImmuPharma" or the "Company")
Repayment of Convertible Security
ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the
specialist drug discovery and development company, stated in its
announcement on 2 September 2020 that following the placing, both
Lind Global Macro Fund, LP ("Lind") and L1 Capital Global Master
Opportunities Fund ("L1") had the right to require repayment of a
portion of their convertible security issued pursuant to the
convertible security deed dated 10 June 2020, details of which were
announced by the Company on 11 June 2020.
The Company announces that Lind has requested repayment of part
of its convertible security. The amount to be repaid in accordance
with the terms of the convertible security deed is $1,068,762.50
leaving an amount outstanding under the Lind convertible security
of $355,112.50 .
L1 has not exercised its right to repayment.
Following the repayment the Company still expects to have
sufficient cash resources to fund operations through the end of
2023.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Stanford Capital Partners (Joint Broker) +44 (0) 203 36 8 3550
Patrick Claridge
John Howes
Bob Pountney +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Gunther De Backer +32 (0) 475 903 909
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases, anti-infectives,
metabolic diseases and cancer. The lead program, Lupuzor(TM), is a
first-in class autophagy immunomodulator which is in Phase III for
the treatment of systemic lupus erythematosus (lupus / SLE). Lupus
is an autoimmune disease which if left untreated can be fatal.
Preclinical analysis suggest therapeutic activity for many other
autoimmune diseases that share the same autophagy mechanism of
action. ImmuPharma and Avion Pharmaceuticals signed on 28 November
2019, an exclusive licence and development agreement and trademark
agreement for Lupuzor(TM) to fund a new international Phase III
trial for Lupuzor(TM) and commercialise in the US. For additional
information about ImmuPharma please visit www.immupharma.com.
ImmuPharma's LEI (Legal Entity Identifier) code:
213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCMZGZLMMMGGZZ
(END) Dow Jones Newswires
September 22, 2020 02:00 ET (06:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024